CXCL10 and COVID-19: In our study, we assessed the levels of TRAIL and IP-10, as well as Nab inhibition against Omicron subvariants BA.1, BA.2, and BA.4/5 SARS-CoV-2 in Group B, comprising individuals who had received three doses of COVID-19 vaccine and had a confirmed COVID-19 diagnosis.